Gene · 3811
Papers2,526
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,526
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of KIR3DL1*0080105, KIR3DL1*0150224 and KIR2DL4*060 by Next Generation Sequencing. | HLA | 2025 | 40862367 | PubTator, text mining | PubMed |
| A novel and robust feature selection method with FDR control for omics-wide association analysis. | PLoS One | 2025 | 40845052 | PubTator, text mining | PubMed |
| Profiling associations of interactive ligand-receptors (HLA class I and KIR gene products) with the progression to type 1 diabetes among seroconverted participants. | Diabetologia | 2025 | 40835749 | PubTator, text mining | PubMed |
| Culturing Potential: advances in ex vivo cell culture systems for haematopoietic cell-based regenerative therapies. | Regen Ther | 2025 | 40704043 | PubTator, text mining | PubMed |
| Prediction of KIR3DL1 and human leukocyte antigen binding. | J Biol Chem | 2025 | 40609790 | PubTator, text mining | PubMed |
| Complete CD16A Deficiency and Defective NK Cell Function in a Man Living with HIV. | J Clin Immunol | 2025 | 40411624 | PubTator, text mining | PubMed |
| The Impact of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen-E, Human Leukocyte Antigen-G Polymorphisms on Innate Immunity and COVID-19 Severity. | J Immunol Res | 2025 | 40391199 | PubTator, text mining | PubMed |
| Peptide selectivity of killer cell immunoglobulin-like receptors differs with allotypic variation in HLA class I. | J Immunol | 2025 | 40127639 | PubTator, text mining | PubMed |
| HLA-A*03 may confer protection against long COVID through an enhanced immune response. | Infect Dis Now | 2025 | 40107360 | PubTator, text mining | PubMed |
| Host Response Stratification in Malarial and Non-malarial Sepsis: A Prospective, Multicenter Analysis From Uganda. | Crit Care Med | 2025 | 39937058 | PubTator, text mining | PubMed |
| Comment on 'Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder' by Wobser et al. | Br J Dermatol | 2025 | 39670606 | PubTator, text mining | PubMed |
| KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study. | Blood Neoplasia | 2024 | 40453521 | PubTator, text mining | PubMed |
| Novel pyroptosis-immune-related lncRNA signature exhibits a distinct immune cell infiltration landscape in breast cancer. | Front Immunol | 2024 | 39906743 | PubTator, text mining | PubMed |
| Recognition of Novel KIR2DL1*0040135, KIR2DL1*112, KIR2DL1*0040136, KIR3DL1*0010122 Alleles From India. | HLA | 2024 | 39721044 | PubTator, text mining | PubMed |
| Phenotypic characterization of NK cells in 5-year-old children exposed to maternal HIV and antiretroviral therapy in early-life. | BMC Immunol | 2024 | 39702040 | PubTator, text mining | PubMed |
| IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CP. | EJHaem | 2024 | 39691242 | PubTator, text mining | PubMed |
| An archaic HLA class I receptor allele diversifies natural killer cell-driven immunity in First Nations peoples of Oceania. | Cell | 2024 | 39476840 | PubTator, text mining | PubMed |
| Analysis of KIR and HLA Polymorphism in Chinese Individuals With COVID-19. | HLA | 2024 | 39364548 | PubTator, text mining | PubMed |
| Characterisation of novel KIR alleles: KIR3DL3*0070105, KIR3DL3*0130202, KIR3DL1*0080104 and KIR3DL1*0010121. | HLA | 2024 | 39291308 | PubTator, text mining | PubMed |
| Abstracts Presented at the 2024 WIN Symposium in Partnership with Burjeel Holdings: March 1-2, 2024, Abu Dhabi, United Arab Emirates. | J Immunother Precis Oncol | 2024 | 39219997 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3811/papers?page=3